ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42827286

A Real-World Study of Patients with FGFR-Altered Advanced Solid Tumors after Exhaustion of Standard-of-Care Treatment.

Demirdjian L and 7 others. Cancer Res Commun, 2026.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A Real-World Study of Patients with FGFR-Altered Advanced Solid Tumors after Exhaustion of Standard-of-Care Treatment. Papers, record 42827286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42827286

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Real-World Study of Patients with FGFR-Altered Advanced Solid Tumors after Exhaustion of Standard-of-Care Treatment.
Journal
Cancer Res Commun
Year
2026
Publication types
Journal Article, Observational Study
Revised in PubMed
2026-10-22

Source PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Demirdjian LLevonhttps://orcid.org/0000-0002-1854-3658
2Sweiti HHusseinhttps://orcid.org/0000-0002-8983-6052
3Harvey RRaymondhttps://orcid.org/0000-0002-6795-519X
4Standish KKristopherhttps://orcid.org/0009-0006-6200-6952
5Stone NNicolehttps://orcid.org/0009-0007-0933-222X
6Baculea SSimonahttps://orcid.org/0009-0005-8546-4617
7Greshock JJoelhttps://orcid.org/0000-0001-6567-4266
8Triantos SSpyroshttps://orcid.org/0009-0006-5599-5393

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Receptors, Fibroblast Growth FactorMajor topic
Humans
Female
Retrospective Studies
Middle Aged
Male
Mutation
Aged
Standard of Care
Adult

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Johnson and Johnson Pharmaceutical Research and Development (J&JPRD)PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132,962,091FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.Int J Mol Sci2020https://conductscience.org/library/papers/32962091PubMed
239,325,014Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.Clin Cancer Res2024https://conductscience.org/library/papers/39325014PubMed
333,968,743A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers.Front Oncol2021https://conductscience.org/library/papers/33968743PubMed
440,239,140Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials.JCO Precis Oncol2025https://conductscience.org/library/papers/40239140PubMed
539,796,710The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies.Cancers (Basel)2024https://conductscience.org/library/papers/39796710PubMed
640,521,274Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer.Eur Urol Open Sci2025https://conductscience.org/library/papers/40521274PubMed
735,176,457FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.Ann Oncol2022https://conductscience.org/library/papers/35176457PubMed
837,541,273Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.Lancet Oncol2023https://conductscience.org/library/papers/37541273PubMed
935,986,088Confidence bands in survival analysis.Br J Cancer2022https://conductscience.org/library/papers/35986088PubMed
1037,870,920Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2023https://conductscience.org/library/papers/37870920PubMed

1 to 10 of 25

See all 25 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42827286

GET https://conductscience.org/api/papers/v1/42827286/references?page=2

API referenceFor AI assistants